非肌層浸潤性膀胱腫瘤膀胱灌注治療進展_West China Medical Journal

Authors：

 李金洪 ¹ , 張朝暉 ² , 員海超 ¹ ,  韓平 ¹

1. ;
2. ;

Corresponding?author：

韓平, Email: hanping@scu.edu.cn

Keywords：

膀胱腫瘤; 灌注治療; 藥物療法

DOI：

10.7507/1002-0179.20140300

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

膀胱腫瘤是泌尿系統常見的惡性腫瘤。經尿道膀胱腫瘤電切術是治療非肌層浸潤性膀胱腫瘤的有效方法，但術后存在較高的腫瘤復發與進展風險,膀胱灌注治療的應用在一定程度上降低了膀胱腫瘤術后復發與進展風險。近年來，研究者們針對膀胱灌注治療的藥物、療程方案及臨床新藥的研發等進行了大量的臨床研究,旨在更好提高灌注療效，降低術后復發，減少不良反應的發生。現就近年來非肌層浸潤性膀胱腫瘤膀胱灌注治療的新進展予以闡述與總結。

Citation： 李金洪, 張朝暉, 員海超, 韓平. 非肌層浸潤性膀胱腫瘤膀胱灌注治療進展. West China Medical Journal, 2014, 29(5): 982-987. doi: 10.7507/1002-0179.20140300 Copy

1.	Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2013[J]. Eur Urol, 2013, 64(4):639-653.
2.	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
3.	溫登瑰, 單保恩, 張思維, 等. 2003-2007年中國腫瘤登記地區膀胱癌的發病與死亡分析[J]. 腫瘤, 2012, 32(4):256-262.
4.	Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer:a critical analysis of currently available drugs, treatment schedules, and long-term results[J]. Eur Urol, 2008, 53(1):45-52.
5.	Mariappan P, Zachou A, Grigor KM, et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience[J]. Eur Urol, 2010, 57(5):843-849.
6.	Williams SK, Hoenig DM, Ghavamian R, et al. Intravesical therapy for bladder cancer[J]. Expert Opin Pharmacother, 2010, 11(6):947-958.
7.	Clarke NS, Basu S, Prescott S, et al. Chemo-prevention in superficial bladder cancer using mitomycin C:a survey of the practice patterns of British urologists[J]. BJU Int, 2006, 97(4):716-719.
8.	Nilsson S, Ragnhammar P, Glimelius B, et al. A systematic overview of chemotherapy effects in urothelial bladder cancer[J]. Acta Oncol, 2001, 40(2-3):371-390.
9.	De Nunzio C, Carbone A, Albisinni S, et al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer:prospective, single-centre randomised trial[J]. World J Urol, 2011, 29(4):517-521.
10.	Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer:a meta-analysis of published results of randomized clinical trials[J]. J Urol, 2004, 171(6 Pt 1):2186-2190, quiz 2435.
11.	Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C:results of a randomized phase Ⅲ trial[J]. J Natl Cancer Inst, 2001, 93(8):597-604.
12.	Huland H, Kl?ppel G, Feddersen I, et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma:final evaluation of a prospective multicenter study with 419 patients[J]. J Urol, 1990, 144(1):68-71; discussion 71-72.
13.	Conrad S, Friedrich MG, Schwaibold H, et al. Long term prophylaxis with mitomycin C(MMC) further reduces tumor recurrence compared to short term prophylaxis with MMC or bacillus Calmette-Guerin (BCG)[J]. J Urol, 2004, 171(4):71.
14.	Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma[J]. Cancer, 2002, 94(9):2363-2368.
15.	Arakawa M, Nakamura K, Yamada Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer:Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect[J]. Exp Ther Med, 2011, 2(5):901-905.
16.	高建國, 田濤, 宋亞林, 等. 圍手術期大劑量吡柔比星膀胱灌注預防膀胱癌復發的臨床觀察[J]. 中華外科雜志, 2010, 48(21):1650-1652.
17.	Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus Bacille Calmette-Guérin after initial Bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer:a multicenter prospective randomized trial[J]. Cancer, 2010, 116(8):1893-1900.
18.	B?hle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder:a randomised, double-blind, placebo-controlled phase Ⅲ multicentre study[J]. Eur Urol, 2009, 56(3):495-503.
19.	Puri R, Palit V, Loadman PM, et al. PhaseⅠ/Ⅱ pilot study of intravesical apaziquone (EO9) for superficial bladder cancer[J]. J Urol, 2006, 176(4 Pt 1):1344-1348.
20.	van der Heijden AG, Moonen PM, Cornel EB, et al. PhaseⅡ marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer:toxicity and marker response[J]. J Urol, 2006, 176(4 Pt 1):1349-1353.
21.	Hendricksen K, Cornel EB, de Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer[J]. J Urol, 2012, 187(4):1195-1199.
22.	Lu CC, Lin MY, Chen SY, et al. The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder[J]. BMC Complement Altern Med, 2013, 23(13):44.
23.	Di Stasi SM, Storti L, Giurioli A, et al. Single immediate preoperative instillation of electromotive mitomycin-C plus transurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C for pTa bladder tumors:long-term results of a prospective randomized trial[J]. J Urol, 2008, 179(Suppl 4):585.
24.	Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer:a randomised controlled trial[J]. Lancet Oncol, 2011, 12(9):871-879.
25.	劉克普, 薛慶, 張更, 等. 術前早期膀胱內灌注吡柔比星預防非肌層浸潤性膀胱癌術后復發療效分析[J]. 現代泌尿生殖腫瘤雜志, 2010, 2(6):357-358, 360.
26.	Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors[J]. J Urol, 1976, 116(2):180-183.
27.	Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer:a meta-analysis of randomized trials[J]. BJU Int, 2004, 93(4):485-490.
28.	Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials[J]. Urology, 2006, 67(6):1216-1223.
29.	B?hle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer:formal meta-analysis of comparative studies on tumor progression[J]. Urology, 2004, 63(4):682-686.
30.	Shang PF, Kwong J, Wang ZP, et al. Intravesical bacillus Calmette-Guérin versus epirubicin for ta and T1 bladder cancer[J]. Cochrane Database Syst Rev, 2011, 11(5):CD006885.
31.	Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer:a 10-year follow-up[J]. J Urol, 1992, 147(4):1020-1023.
32.	Kumar A, Dubey D, Bansal P, et al. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer[J]. J Urol, 2002, 168(5):2232-2235.
33.	Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer:a meta-analysis of the published results of randomized clinical trials[J]. J Urol, 2002, 168(5):1964-1970.
34.	van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increase toxicity:results from a European organisation for research and treatment of cancer Genito-Urinary group phaseⅢ trial[J]. Eur Urol, 2003, 44(4):429-434.
35.	Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer:results of a randomized, prospective, double-blind, placebo controlled, multicenter study[J]. J Urol, 2006, 176(3):935-939.
36.	Baron S, Tyring SK, Fleischmann WR, et al. The interferons. Mechanisms of action and clinical applications[J]. JAMA, 1991, 266(10):1375-1383.
37.	Moltó L, Alvarez-Mon M, Carballido J, et al. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer[J]. Cancer, 1995, 75(11):2720-2726.
38.	Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer:a Northern California Oncology Group Study[J]. J Clin Oncol, 1988, 6(3):476-483.
39.	Portillo J, Martin B, Hernandez R, et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder[J]. Urology, 1997, 49(2):187-190.
40.	K?lble T, Beer M, Mendoza E, et al. BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study[J]. Urologe A, 1994, 33(2):133-137.
41.	Joudi FN, Smith BJ, O' donnell MA, et al. Final results from a National multicenter phaseⅡ trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer[J]. Urol Oncol, 2006, 24(4):344-348.
42.	Bazarbashi S, Soudy H, Abdelsalam M, et al. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder[J]. BJU Int, 2011, 108(7):1115-1118.
43.	Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer[J]. J Urol, 2001, 165(6 Pt 1):1904-1907.
44.	Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer:a single-center study[J]. Urology, 2003, 61(2):338-341.
45.	Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)[J]. BJU Int, 2011, 107(6):912-918.
46.	Chen CH, Yang HJ, Shun CT, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer[J]. Urol Oncol, 2012, 30(4):421-427.

1. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2013[J]. Eur Urol, 2013, 64(4):639-653.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
3. 溫登瑰, 單保恩, 張思維, 等. 2003-2007年中國腫瘤登記地區膀胱癌的發病與死亡分析[J]. 腫瘤, 2012, 32(4):256-262.
4. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer:a critical analysis of currently available drugs, treatment schedules, and long-term results[J]. Eur Urol, 2008, 53(1):45-52.
5. Mariappan P, Zachou A, Grigor KM, et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience[J]. Eur Urol, 2010, 57(5):843-849.
6. Williams SK, Hoenig DM, Ghavamian R, et al. Intravesical therapy for bladder cancer[J]. Expert Opin Pharmacother, 2010, 11(6):947-958.
7. Clarke NS, Basu S, Prescott S, et al. Chemo-prevention in superficial bladder cancer using mitomycin C:a survey of the practice patterns of British urologists[J]. BJU Int, 2006, 97(4):716-719.
8. Nilsson S, Ragnhammar P, Glimelius B, et al. A systematic overview of chemotherapy effects in urothelial bladder cancer[J]. Acta Oncol, 2001, 40(2-3):371-390.
9. De Nunzio C, Carbone A, Albisinni S, et al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer:prospective, single-centre randomised trial[J]. World J Urol, 2011, 29(4):517-521.
10. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer:a meta-analysis of published results of randomized clinical trials[J]. J Urol, 2004, 171(6 Pt 1):2186-2190, quiz 2435.
11. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C:results of a randomized phase Ⅲ trial[J]. J Natl Cancer Inst, 2001, 93(8):597-604.
12. Huland H, Kl?ppel G, Feddersen I, et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma:final evaluation of a prospective multicenter study with 419 patients[J]. J Urol, 1990, 144(1):68-71; discussion 71-72.
13. Conrad S, Friedrich MG, Schwaibold H, et al. Long term prophylaxis with mitomycin C(MMC) further reduces tumor recurrence compared to short term prophylaxis with MMC or bacillus Calmette-Guerin (BCG)[J]. J Urol, 2004, 171(4):71.
14. Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2"R)-4'-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma[J]. Cancer, 2002, 94(9):2363-2368.
15. Arakawa M, Nakamura K, Yamada Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer:Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect[J]. Exp Ther Med, 2011, 2(5):901-905.
16. 高建國, 田濤, 宋亞林, 等. 圍手術期大劑量吡柔比星膀胱灌注預防膀胱癌復發的臨床觀察[J]. 中華外科雜志, 2010, 48(21):1650-1652.
17. Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus Bacille Calmette-Guérin after initial Bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer:a multicenter prospective randomized trial[J]. Cancer, 2010, 116(8):1893-1900.
18. B?hle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder:a randomised, double-blind, placebo-controlled phase Ⅲ multicentre study[J]. Eur Urol, 2009, 56(3):495-503.
19. Puri R, Palit V, Loadman PM, et al. PhaseⅠ/Ⅱ pilot study of intravesical apaziquone (EO9) for superficial bladder cancer[J]. J Urol, 2006, 176(4 Pt 1):1344-1348.
20. van der Heijden AG, Moonen PM, Cornel EB, et al. PhaseⅡ marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer:toxicity and marker response[J]. J Urol, 2006, 176(4 Pt 1):1349-1353.
21. Hendricksen K, Cornel EB, de Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer[J]. J Urol, 2012, 187(4):1195-1199.
22. Lu CC, Lin MY, Chen SY, et al. The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder[J]. BMC Complement Altern Med, 2013, 23(13):44.
23. Di Stasi SM, Storti L, Giurioli A, et al. Single immediate preoperative instillation of electromotive mitomycin-C plus transurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C for pTa bladder tumors:long-term results of a prospective randomized trial[J]. J Urol, 2008, 179(Suppl 4):585.
24. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer:a randomised controlled trial[J]. Lancet Oncol, 2011, 12(9):871-879.
25. 劉克普, 薛慶, 張更, 等. 術前早期膀胱內灌注吡柔比星預防非肌層浸潤性膀胱癌術后復發療效分析[J]. 現代泌尿生殖腫瘤雜志, 2010, 2(6):357-358, 360.
26. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors[J]. J Urol, 1976, 116(2):180-183.
27. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer:a meta-analysis of randomized trials[J]. BJU Int, 2004, 93(4):485-490.
28. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials[J]. Urology, 2006, 67(6):1216-1223.
29. B?hle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer:formal meta-analysis of comparative studies on tumor progression[J]. Urology, 2004, 63(4):682-686.
30. Shang PF, Kwong J, Wang ZP, et al. Intravesical bacillus Calmette-Guérin versus epirubicin for ta and T1 bladder cancer[J]. Cochrane Database Syst Rev, 2011, 11(5):CD006885.
31. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer:a 10-year follow-up[J]. J Urol, 1992, 147(4):1020-1023.
32. Kumar A, Dubey D, Bansal P, et al. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer[J]. J Urol, 2002, 168(5):2232-2235.
33. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer:a meta-analysis of the published results of randomized clinical trials[J]. J Urol, 2002, 168(5):1964-1970.
34. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increase toxicity:results from a European organisation for research and treatment of cancer Genito-Urinary group phaseⅢ trial[J]. Eur Urol, 2003, 44(4):429-434.
35. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer:results of a randomized, prospective, double-blind, placebo controlled, multicenter study[J]. J Urol, 2006, 176(3):935-939.
36. Baron S, Tyring SK, Fleischmann WR, et al. The interferons. Mechanisms of action and clinical applications[J]. JAMA, 1991, 266(10):1375-1383.
37. Moltó L, Alvarez-Mon M, Carballido J, et al. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer[J]. Cancer, 1995, 75(11):2720-2726.
38. Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer:a Northern California Oncology Group Study[J]. J Clin Oncol, 1988, 6(3):476-483.
39. Portillo J, Martin B, Hernandez R, et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder[J]. Urology, 1997, 49(2):187-190.
40. K?lble T, Beer M, Mendoza E, et al. BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study[J]. Urologe A, 1994, 33(2):133-137.
41. Joudi FN, Smith BJ, O' donnell MA, et al. Final results from a National multicenter phaseⅡ trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer[J]. Urol Oncol, 2006, 24(4):344-348.
42. Bazarbashi S, Soudy H, Abdelsalam M, et al. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder[J]. BJU Int, 2011, 108(7):1115-1118.
43. Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer[J]. J Urol, 2001, 165(6 Pt 1):1904-1907.
44. Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer:a single-center study[J]. Urology, 2003, 61(2):338-341.
45. Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)[J]. BJU Int, 2011, 107(6):912-918.
46. Chen CH, Yang HJ, Shun CT, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer[J]. Urol Oncol, 2012, 30(4):421-427.

Previous Article
Normalized Management of Dual Referral between Large Comprehensive Hospital and Community Helath Service Centers
Next Article
乳腺癌干細胞的研究進展

West China Medical Journal

非肌層浸潤性膀胱腫瘤膀胱灌注治療進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content